- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02621905
Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg
Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions
Study Overview
Detailed Description
After confirmation of eligibility, participants will be randomly assigned 1:1 to commence therapy with either 100mg mane and 100mg nocte for 21 days or Sporanox 200mg mane and 200mg nocte with food for 21 days. If a subject enters the study already receiving itraconazole prophylaxis at a dose of itraconazole higher than 100 mg twice a day, the subject will then be dosed on study at the pre-study dosage; that is, the subject will take the same number of capsules per day on study as the subject was taking prior to enrolment in the study.
The following information will be collected at baseline; whether the participant is taking itraconazole prophylaxis and at what dose; whether the participant is taking gastric suppression therapy. Patients who are not taking food or who are taking gastric acid suppression therapy (antacids, an H2 antagonist or a proton pump inhibitor) can take Sporanox with cola or orange juice to maximise absorption as recommended in the Sporanox product label (not required for Lozanoc formulation).
At Day 22, participants assigned to
- Lozanoc and who have completed 21 days of Lozanoc prophylaxis will cross over to the same number of Sporanox capsules with food for a further 21 days
- Sporanox and who have completed 21 days of Sporanox prophylaxis will cross over to the same number of Lozanoc capsules for a further 21 days.
The dose of either drug may be dose-reduced or ceased for toxicity at the discretion of the investigator.
During the course of the treatment periods participants will undergo the following assessments:
- Concurrent medication(s)
- Clinical adverse events
- Measurement of vital signs (weight, blood pressure, temperature)
- Targeted physical examination
- Documentation of any evidence of systemic fungal infection
- Medication and meal diaries
- 12-lead electrocardiogram (ECG)
- Laboratory safety assessments: Renal function and electrolytes (urea, creatinine, estimated glomerular filtration rate [eGFR], sodium, potassium, chloride, bicarbonate), Liver function tests (bilirubin, albumin, total protein, alanine aminotransferase [ALT], aspartate aminotransferase [AST])
- Pharmacokinetic testing: Trough (pre-morning dose; 0 hr) sample will be collected at Baseline (Day 1), and at Days 8, 15, 22, 29, 36 and 43. Post-dose samples will also be collected 2, 3.5 and 6 hours after the morning dose on Day 22 and Day 43
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincent's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of written, informed consent
- Age of at least 18 years
- No clinical evidence of active systemic fungal infection
- Physician-recommended primary prophylaxis against systemic fungal infections with itraconazole in patients who have had or about to have: a heart, lung or bone marrow transplant, combination chemotherapy for cancer; aspergilloma, chronic pulmonary aspergillus bronchitis, or allergic bronchopulmonary aspergillosis
- Patients may be receiving itraconazole prophylaxis prior to entry into the study
- Body mass index between 15.0 and 35.0 kg/m2
Exclusion Criteria:
- Pregnant, planning pregnancy or breastfeeding
- Congestive cardiac failure or other causes of ventricular dysfunction that may outweigh the benefit of itraconazole
- Hypersensitivity to either study drug or to any of their excipients
Coadministration of the following drugs:
- CYP3A4 metabolised substrates that can prolong the QT-interval e.g., sertindole, terfenadine
- CYP3A4 metabolised HMG-CoA reductase inhibitors e.g. simvastatin, lovastatin
- Potent CYP3A4 inhibitors e.g. dronedarone
- Triazolam, alprazolam and oral midazolam
- Ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine) and ergotamine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sporanox
100 mg
|
At least 2 capsules twice a day for 3 weeks
Other Names:
|
Experimental: Lozanoc
50 mg
|
At least 2 capsules twice a day for 3 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relative steady-state bioavailability
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Deborah Marriott, St Vincent's Hospital, Sydney
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Agranulocytosis
- Leukopenia
- Leukocyte Disorders
- Neutropenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
- Hydroxyitraconazole
Other Study ID Numbers
- MPG010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neutropenia
-
Hospira, now a wholly owned subsidiary of PfizerCompletedSolid Tumors | Malignant Hemopathy | Chemotherapy-induced Febrile Neutropenia (FN)France
-
TTY BiopharmCompletedNeutropenia, FebrileTaiwan
-
University of Mississippi Medical CenterUnknownPediatric Cancer | Chemotherapy-Induced Febrile Neutropenia | Chemotherapy-induced Neutropenia | Granulocyte Colony-Stimulating FactorUnited States
-
Institut RafaelActive, not recruitingPatient Satisfaction | Patient Preference | Febrile Neutropenia, Drug-InducedFrance
-
University Hospital, BrestCompletedNeutropenia, FebrileFrance
-
CinnagenCompletedChemotherapy-induced Neutropenia
-
University Hospital Inselspital, BerneCompletedFebrile Neutropenia | Pediatric Cancer | Oncology | Chemotherapy-induced NeutropeniaSwitzerland
-
University Hospital Inselspital, BerneCompletedFebrile Neutropenia | Pediatric Cancer | Oncology | Chemotherapy-induced NeutropeniaSwitzerland
-
PfizerCompletedNon-Interventional StudyGermany
-
BeyondSpring Pharmaceuticals Inc.CompletedChemotherapy-induced NeutropeniaChina, Russian Federation, United States, Ukraine
Clinical Trials on Sporanox
-
Cell>Point LLCUnknownCoronary Artery DiseaseUnited States
-
Hoffmann-La RocheCompleted
-
Stanford UniversityTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Boryung Pharmaceutical Co., LtdCompletedCandidiasis | Dermatomycoses | Histoplasmosis | Superficial MycosesKorea, Republic of
-
Janssen Korea, Ltd., KoreaCompleted
-
PfizerArvinas Estrogen Receptor, Inc.Completed
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors | Relapsed/Refractory LymphomaUnited States
-
AstraZenecaCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States
-
Stanford UniversityCompletedSkin Cancer | Basal Cell Carcinoma (BCC)United States
-
PfizerCompleted